Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae

Shinichi Toyooka, Michele Carbone, Kiyomi O. Toyooka, Maurizio Bocchetta, Narayan Shivapurkar, John D. Minna, Adi F. Gazdar

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Cancer patients receiving chemotherapy are prone to develop infections that might postpone treatment and lead to complications. The aim of our study was to investigate whether a heterogeneous population of patients with solid tumors and malignant lymphoma undergoing chemotherapy would respond serologically to vaccination against influenza and pneumococcal disease. There are no established routines in oncology departments in Norway regarding vaccination of these patients. The study included 35 cancer patients with median age 53 yr (range 20-74) and 38 controls with median age 57 yr (range 43-75). The chemotherapy regimens used were mild or moderately immunosuppressive. After one vaccination, 25 patients (72%) and 34 controls (87%) were serologically protected against two or three influenza strains. A higher proportion of patients with solid tumors (81%) than lymphoma (38%) achieved protection. Age, months on chemotherapy, and curative versus palliative treatment did not influence responses to vaccination. After vaccination with a 23-valent polysaccharide vaccine against pneumococci, most patients and controls achieved protective serum levels of antibodies against the different serotypes, with the exception that fewer patients were protected against serotype 4. The responses in controls were, however, generally stronger to all serotypes. Tumor type did not influence this vaccination response. We conclude that our cancer patients achieved adequate responses to influenza virus and Streptococcus pneumoniae. These are not live vaccines and are therefore safe for immunocompromised patients. Routine vaccinations against influenza virus and Streptococcus pneumoniae should be considered in cancer patients undergoing mild to moderately immunosuppressive chemotherapy.

Original languageEnglish
Pages (from-to)71-78
Number of pages8
JournalMedical Oncology
Volume19
Issue number2
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Streptococcus pneumoniae
Orthomyxoviridae
Vaccination
Drug Therapy
Neoplasms
Immunosuppressive Agents
Human Influenza
Lymphoma
Immunocompromised Host
Norway
Palliative Care
Polysaccharides
Vaccines
Antibodies

Keywords

  • Chemotherapy
  • Immunosuppression
  • Response to vaccination
  • Solid tumors and lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. / Toyooka, Shinichi; Carbone, Michele; Toyooka, Kiyomi O.; Bocchetta, Maurizio; Shivapurkar, Narayan; Minna, John D.; Gazdar, Adi F.

In: Medical Oncology, Vol. 19, No. 2, 2002, p. 71-78.

Research output: Contribution to journalArticle

Toyooka, Shinichi ; Carbone, Michele ; Toyooka, Kiyomi O. ; Bocchetta, Maurizio ; Shivapurkar, Narayan ; Minna, John D. ; Gazdar, Adi F. / Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. In: Medical Oncology. 2002 ; Vol. 19, No. 2. pp. 71-78.
@article{638043566d8a495a8361555b86b2420c,
title = "Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae",
abstract = "Cancer patients receiving chemotherapy are prone to develop infections that might postpone treatment and lead to complications. The aim of our study was to investigate whether a heterogeneous population of patients with solid tumors and malignant lymphoma undergoing chemotherapy would respond serologically to vaccination against influenza and pneumococcal disease. There are no established routines in oncology departments in Norway regarding vaccination of these patients. The study included 35 cancer patients with median age 53 yr (range 20-74) and 38 controls with median age 57 yr (range 43-75). The chemotherapy regimens used were mild or moderately immunosuppressive. After one vaccination, 25 patients (72{\%}) and 34 controls (87{\%}) were serologically protected against two or three influenza strains. A higher proportion of patients with solid tumors (81{\%}) than lymphoma (38{\%}) achieved protection. Age, months on chemotherapy, and curative versus palliative treatment did not influence responses to vaccination. After vaccination with a 23-valent polysaccharide vaccine against pneumococci, most patients and controls achieved protective serum levels of antibodies against the different serotypes, with the exception that fewer patients were protected against serotype 4. The responses in controls were, however, generally stronger to all serotypes. Tumor type did not influence this vaccination response. We conclude that our cancer patients achieved adequate responses to influenza virus and Streptococcus pneumoniae. These are not live vaccines and are therefore safe for immunocompromised patients. Routine vaccinations against influenza virus and Streptococcus pneumoniae should be considered in cancer patients undergoing mild to moderately immunosuppressive chemotherapy.",
keywords = "Chemotherapy, Immunosuppression, Response to vaccination, Solid tumors and lymphoma",
author = "Shinichi Toyooka and Michele Carbone and Toyooka, {Kiyomi O.} and Maurizio Bocchetta and Narayan Shivapurkar and Minna, {John D.} and Gazdar, {Adi F.}",
year = "2002",
doi = "10.1385/MO:19:2:71",
language = "English",
volume = "19",
pages = "71--78",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae

AU - Toyooka, Shinichi

AU - Carbone, Michele

AU - Toyooka, Kiyomi O.

AU - Bocchetta, Maurizio

AU - Shivapurkar, Narayan

AU - Minna, John D.

AU - Gazdar, Adi F.

PY - 2002

Y1 - 2002

N2 - Cancer patients receiving chemotherapy are prone to develop infections that might postpone treatment and lead to complications. The aim of our study was to investigate whether a heterogeneous population of patients with solid tumors and malignant lymphoma undergoing chemotherapy would respond serologically to vaccination against influenza and pneumococcal disease. There are no established routines in oncology departments in Norway regarding vaccination of these patients. The study included 35 cancer patients with median age 53 yr (range 20-74) and 38 controls with median age 57 yr (range 43-75). The chemotherapy regimens used were mild or moderately immunosuppressive. After one vaccination, 25 patients (72%) and 34 controls (87%) were serologically protected against two or three influenza strains. A higher proportion of patients with solid tumors (81%) than lymphoma (38%) achieved protection. Age, months on chemotherapy, and curative versus palliative treatment did not influence responses to vaccination. After vaccination with a 23-valent polysaccharide vaccine against pneumococci, most patients and controls achieved protective serum levels of antibodies against the different serotypes, with the exception that fewer patients were protected against serotype 4. The responses in controls were, however, generally stronger to all serotypes. Tumor type did not influence this vaccination response. We conclude that our cancer patients achieved adequate responses to influenza virus and Streptococcus pneumoniae. These are not live vaccines and are therefore safe for immunocompromised patients. Routine vaccinations against influenza virus and Streptococcus pneumoniae should be considered in cancer patients undergoing mild to moderately immunosuppressive chemotherapy.

AB - Cancer patients receiving chemotherapy are prone to develop infections that might postpone treatment and lead to complications. The aim of our study was to investigate whether a heterogeneous population of patients with solid tumors and malignant lymphoma undergoing chemotherapy would respond serologically to vaccination against influenza and pneumococcal disease. There are no established routines in oncology departments in Norway regarding vaccination of these patients. The study included 35 cancer patients with median age 53 yr (range 20-74) and 38 controls with median age 57 yr (range 43-75). The chemotherapy regimens used were mild or moderately immunosuppressive. After one vaccination, 25 patients (72%) and 34 controls (87%) were serologically protected against two or three influenza strains. A higher proportion of patients with solid tumors (81%) than lymphoma (38%) achieved protection. Age, months on chemotherapy, and curative versus palliative treatment did not influence responses to vaccination. After vaccination with a 23-valent polysaccharide vaccine against pneumococci, most patients and controls achieved protective serum levels of antibodies against the different serotypes, with the exception that fewer patients were protected against serotype 4. The responses in controls were, however, generally stronger to all serotypes. Tumor type did not influence this vaccination response. We conclude that our cancer patients achieved adequate responses to influenza virus and Streptococcus pneumoniae. These are not live vaccines and are therefore safe for immunocompromised patients. Routine vaccinations against influenza virus and Streptococcus pneumoniae should be considered in cancer patients undergoing mild to moderately immunosuppressive chemotherapy.

KW - Chemotherapy

KW - Immunosuppression

KW - Response to vaccination

KW - Solid tumors and lymphoma

UR - http://www.scopus.com/inward/record.url?scp=4243694895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4243694895&partnerID=8YFLogxK

U2 - 10.1385/MO:19:2:71

DO - 10.1385/MO:19:2:71

M3 - Article

C2 - 12180483

AN - SCOPUS:4243694895

VL - 19

SP - 71

EP - 78

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -